User menu

Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population

Bibliographic reference Moussaoui , Samira ; Saussoy, Pascale ; Ambroise, Jérôme ; Defour, Jean-Philippe ; Zouitene, Raouf ; et. al. Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population. In: Clinical and Applied Thrombosis / Hemostasis, Vol. 23, no. 2, p. 105-115 (2017)
Permanent URL http://hdl.handle.net/2078.1/175966
  1. Lu Yanhui, Zhao Yanfen, Liu Guozhang, Wang Xiaoling, Liu Zhihong, Chen Baiping, Hui Rutai, Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population, 10.1016/s0049-3848(02)00064-6
  2. Rosendaal FR, Venous thrombosis: a multicausal disease, 10.1016/s0140-6736(98)10266-0
  3. Bertina Rogier M., Koeleman Bobby P. C., Koster Ted, Rosendaal Frits R., Dirven Richard J., de Ronde Hans, van der Velden Pieter A., Reitsma Pieter H., Mutation in blood coagulation factor V associated with resistance to activated protein C, 10.1038/369064a0
  4. Kujovich Jody Lynn, Factor V Leiden thrombophilia, 10.1097/gim.0b013e3181faa0f2
  5. Dahlback B, Thromb Haemost, 74, 139 (1995)
  6. Castoldi E., Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations, 10.1182/blood-2003-10-3578
  7. Dahlback B., Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure-Function Relationships and Molecular Recognition, 10.1161/01.atv.0000168421.13467.82
  8. BRUGGE J. M., SIMIONI P., BERNARDI F., TORMENE D., LUNGHI B., TANS G., PAGNAN A., ROSING J., CASTOLDI E., Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation, 10.1111/j.1538-7836.2005.01634.x
  9. Poort SR, Blood, 88, 3698 (1996)
  10. Koster T, Blood, 85, 2756 (1995)
  11. Lane DA, Thromb Haemost, 76, 651 (1996)
  12. Pabinger I., Br??cker S., Kyrle P. A., Schneider B., Korninger H. C., Niessner H., Lechner K., Hereditary deficiency of antithrombin III, protein C and protein S : prevalence in patients with a history of venous thrombosis and criteria for rational patient screening, 10.1097/00001721-199210000-00005
  13. Ridker Paul M., Hennekens Charles H., Lindpaintner Klaus, Stampfer Meir J., Eisenberg Paul R., Miletich Joseph P., Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men, 10.1056/nejm199504063321403
  14. Shen Ming-Ching, Lin Jen-Shiou, Tsay Woei, HIGH PREVALENCE OF ANTITHROMBIN III, PROTEIN C AND PROTEIN S DEFICIENCY, BUT NO FACTOR V LEIDEN MUTATION IN VENOUS THROMBOPHILIC CHINESE PATIENTS IN TAIWAN, 10.1016/s0049-3848(97)00141-2
  15. Shen Ming-Ching, Lin Jen-Shiou, Tsay Woei, Protein C and Protein S Deficiencies Are the Most Important Risk Factors Associated with Thrombosis in Chinese Venous Thrombophilic Patients in Taiwan, 10.1016/s0049-3848(00)00265-6
  16. Eid SS, Clin Lab Sci J Am Soc Med Technol, 15, 196 (2001)
  17. Mohanty D., Das K. C., Al-Hussain H., Naglen P., Eklof B., Marouf Rajaa, Khamis Amal, Al-Majdi M., Thrombophilia in ethnic Arabs in Kuwait, 10.1007/s002770050242
  18. Bouaziz-Borgi Lobna, Almawi Wassim Y., Mtiraoui Nabil, Nsiri Brahim, Keleshian Sose H., Kreidy Raghid, Louzir Bessem, Hezard Nathalie, Mahjoub Touhami, Distinct association of factor V-Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisia and Lebanon, 10.1002/ajh.20582
  19. AMEEN G., IRANI-HAKIME N., FAWAZ N. A., MAHJOUB T., ALMAWI W. Y., An Arab selective gradient in the distribution of factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T, 10.1111/j.1538-7836.2005.01546.x
  20. De Stefano V, Blood, 87, 3531 (1996)
  21. Godeneche G., Gaillard N., Roy L., Mania A., Tondeur S., Chomel J.C., Lavabre T., Arquizan C., Neau J.P., JAK2V617F Mutation Associated with Cerebral Venous Thrombosis: A Report of Five Cases, 10.1159/000267281
  22. BAXTER E, SCOTT L, CAMPBELL P, EAST C, FOUROUCLAS N, SWANTON S, VASSILIOU G, BENCH A, BOYD E, CURTIN N, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, 10.1016/s0140-6736(05)74230-6
  23. James Chloé, Ugo Valérie, Le Couédic Jean-Pierre, Staerk Judith, Delhommeau François, Lacout Catherine, Garçon Loïc, Raslova Hana, Berger Roland, Bennaceur-Griscelli Annelise, Villeval Jean Luc, Constantinescu Stefan N., Casadevall Nicole, Vainchenker William, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, 10.1038/nature03546
  24. COLAIZZO D., AMITRANO L., TISCIA G. L., SCENNA G., GRANDONE E., GUARDASCIONE M. A., BRANCACCIO V., MARGAGLIONE M., The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis : JAK2 V617F mutation and occurrence of PMVT, 10.1111/j.1538-7836.2006.02277.x
  25. Fiorini Alessia, Chiusolo Patrizia, Rossi Elena, Za Tommaso, De Ritis Daniela G., Ciminello Angela, Leone Giuseppe, De Stefano Valerio, Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms, 10.1002/ajh.21335
  26. Klampfl Thorsten, Gisslinger Heinz, Harutyunyan Ashot S., Nivarthi Harini, Rumi Elisa, Milosevic Jelena D., Them Nicole C.C., Berg Tiina, Gisslinger Bettina, Pietra Daniela, Chen Doris, Vladimer Gregory I., Bagienski Klaudia, Milanesi Chiara, Casetti Ilaria Carola, Sant'Antonio Emanuela, Ferretti Virginia, Elena Chiara, Schischlik Fiorella, Cleary Ciara, Six Melanie, Schalling Martin, Schönegger Andreas, Bock Christoph, Malcovati Luca, Pascutto Cristiana, Superti-Furga Giulio, Cazzola Mario, Kralovics Robert, Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms, 10.1056/nejmoa1311347
  27. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., Avezov E., Li J., Kollmann K., Kent D.G., Aziz A., Godfrey A.L., Hinton J., Martincorena I., Van Loo P., Jones A.V., Guglielmelli P., Tarpey P., Harding H.P., Fitzpatrick J.D., Goudie C.T., Ortmann C.A., Loughran S.J., Raine K., Jones D.R., Butler A.P., Teague J.W., O'Meara S., McLaren S., Bianchi M., Silber Y., Dimitropoulou D., Bloxham D., Mudie L., Maddison M., Robinson B., Keohane C., Maclean C., Hill K., Orchard K., Tauro S., Du M.-Q., Greaves M., Bowen D., Huntly B.J.P., Harrison C.N., Cross N.C.P., Ron D., Vannucchi A.M., Papaemmanuil E., Campbell P.J., Green A.R., Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2, 10.1056/nejmoa1312542
  28. Raoul Magali, Mathonnet Florence, Peltier Jean-Yves, Collet Catherine, Boucly Catherine, Van Amerongen Geneviève, Mathieu Bertille, Jaouen Envel, de Mazancourt Philippe, An Improved Method for the Detection of the G20210A Transition in the Prothrombin Gene, 10.1016/s0049-3848(97)00272-7
  29. Dati Francesco, Pelzer Hermann, Wagner Carola, Relevance of Markers of Hemostasis Activation in Obstetrics/Gynecology and Pediatrics, 10.1055/s-2007-996037
  30. Haidl H, Thromb Haemost Stuttg, 95, 772 (2006)
  31. Luyendyk James P., Tilley Rachel E., Mackman Nigel, Genetic susceptibility to thrombosis, 10.1007/s11883-006-0073-1
  32. Chafa O, Br J Haematol, 97, 688 (1997)
  33. Bourouba Romyla, Houcher Bakhouche, Djabi Farida, Eğin Yonca, Akar Nejat, The Prevalence of Methylenetetrahydrofolate Reductase 677 C-T, Factor V 1691 G-A, and Prothrombin 20210 G-A Mutations in Healthy Populations in Sétif, Algeria, 10.1177/1076029608319944
  34. Dashti Ali A., Jadaon Mehrez M., Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals, 10.1007/s11033-010-0474-7
  35. Eid SS, Clin Lab Sci J Am Soc Med Technol, 17, 200 (2003)
  36. Al-Sweedan Suleimman A, Jaradat Said, Iraqi Muna, Beshtawi Mohamed, The prevalence of factor V Leiden (G1691A), prothrombin G20210A and methylenetetrahydrofolate reductase C677T mutations in Jordanian patients with β-thalassemia major : , 10.1097/mbc.0b013e3283315b4f
  37. Almawi Wassim Y., Keleshian Sose H., Borgi Lobna, Fawaz Naglaa A., Abboud Nisreen, Mtiraoui Nabil, Mahjoub Touhami, Varied Prevalence of Factor V G1691A (Leiden) and Prothrombin G20210A Single Nucleotide Polymorphisms Among Arabs, 10.1007/s11239-005-3550-4
  38. Irani-Hakime N, Clin Chem, 46, 134 (2000)
  39. Irani-Hakime Noha, Tamim Hala, Elias Ghanem, Choueiry Salah, Kreidy Raghid, Daccache Jocelyn L., Almawi Wassim Y., 10.1023/a:1011268531377
  40. Ajem A, East Mediterr Health J, 15, 1483 (2009)
  41. Maalej Lobna, Hadjkacem Basma, Ben Amor Ikram, Smaoui Mariem, Gargouri Ali, Gargouri Jalel, Prevalence of factor V Leiden in south Tunisian blood donors, 10.1007/s11239-011-0582-9
  42. Almawi Wassim Y., Tamim Hala, Kreidy Raghid, Timson Georgina, Rahal Elias, Nabulsi Malak, Finan Ramzi R., Irani-Hakime Noha, A Case Control Study on the Contribution of Factor V-Leiden, Prothrombin G20210A, and MTHFR C677T Mutations to the Genetic Susceptibility of Deep Venous Thrombosis, 10.1007/s11239-005-1313-x
  43. Mathonnet F, Thromb Haemost, 88, 1073 (2002)
  44. They-They Thierry Paluku, Hamzi Khalil, Moutawafik Mohamed Taha, Bellayou Hanane, El Messal Mariame, Nadifi Sellama, Prevalence of angiotensin-converting enzyme, methylenetetrahydrofolate reductase, Factor V Leiden, prothrombin and apolipoprotein E gene polymorphisms in Morocco, 10.3109/03014461003738850
  45. Rees D.C., Cox M., Clegg J.B., World distribution of factor V Leiden, 10.1016/s0140-6736(95)91803-5
  46. Jadaon Mehrez Mehrez M., EPIDEMIOLOGY OF ACTIVATED PROTEIN C RESISTANCE AND FACTOR V LEIDEN MUTATION IN THE MEDITERRANEAN REGION, 10.4084/mjhid.2011.037
  47. Ulu A, Turk J Hematol, 23, 100 (2006)
  48. Irani-Hakime Noha, Tamim Hala, Kreidy Raghid, Almawi Wassim Y., The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese, 10.1002/1096-8652(200009)65:1<45::aid-ajh8>3.0.co;2-v
  49. Awidi A, Thromb Haemost, 81, 582 (1999)
  50. Grandone E, Thromb Haemost, 77, 822 (1997)
  51. Lucotte Gérard, Mercier Géraldine, Population Genetics of Factor V Leiden in Europe, 10.1006/bcmd.2001.0388
  52. Poort SR, Blood, 88, 3698 (1996)
  53. Jadaon Mehrez M., EPIDEMIOLOGY OF PROTHROMBIN G20210A MUTATION IN THE MEDITERRANEAN REGION, 10.4084/mjhid.2011.054
  54. Francès Francesc, Portolès Olga, Gabriel Francisco, Corella Dolores, Sorlí José Vicente, Sabater Antonio, Alfonso José L, Guillén Marisa, Comparación de las frecuencias de los alelos factor V Leiden (G1691A) y protrombina-G20210A entre pacientes con trombosis venosa profunda y población general mediterránea española, 10.4067/s0034-98872006000100002
  55. Roldan Vanessa, Lecumberri Ramón, Muñoz-Torrero Juan Francisco Sánchez, Vicente Vicente, Rocha Eduardo, Brenner Benjamin, Monreal Manuel, Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry, 10.1016/j.thromres.2008.11.003
  56. Leroyer C, Thromb Haemost, 80, 49 (1998)
  57. Reny J-L., Alhenc-Gelas M., Fontana P., Bissery A., Julia P. L., Fiessinger J-N., Aiach M., Emmerich J., The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study, 10.1111/j.1538-7836.2004.00809.x
  58. Martinelli Ida, Bucciarelli Paolo, Margaglione Maurizio, De Stefano Valerio, Castaman Giancarlo, Mannucci Pier Mannuccio, The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both, 10.1046/j.1365-2141.2000.02502.x
  59. Cattaneo Marco, Chantarangkul Veena, Taioli Emanuela, Santos José Hermida, Tagliabue Liliana, The G20210A Mutation of the Prothrombin Gene in Patients with Previous First Episodes of Deep-Vein Thrombosis, 10.1016/s0049-3848(98)00136-4
  60. They-They Thierry Paluku, Battas Omar, Slassi Ilham, Rafai Mohamed Abdou, Katumbay Desire Tshala, Nadifi Sellama, Prothrombin G20210A and Factor V Leiden Polymorphisms in Stroke, 10.1007/s12031-011-9580-9
  61. Helley D, Thromb Haemost, 82, 1554 (1999)
  62. Franco R.F., Santos S.E.B., Elion J., Tavella M.H., Zago M.A., Prevalence of the G20210A Polymorphism in the 3'-Untranslated Region of the Prothrombin Gene in Different Human Populations, 10.1159/000040854
  63. Zoossmann-Diskin Avshalom, Gazit Ephraim, Peleg Leah, Shohat Mordechai, Turner David, Thrombophilic polymorphisms in Israel, 10.1016/j.bcmd.2008.05.004
  64. Hessner MJ, Thromb Haemost, 81, 733 (1999)
  65. Rees David C., Chapman Nicola H., Webster Matthew T., Guerreiro Joao F., Rochette Jacques, Clegg John B., Born to clot: the European burden, 10.1111/j.1365-2141.1999.01361.x
  66. Bennett JA, Thromb Haemost, 86, 1592 (2001)
  67. Sottilotta Gianluca, Mammì Corrado, Furlò Giuseppe, Oriana Vincenzo, Latella Caterina, Trapani Lombardo Vincenzo, High Incidence of Factor V Leiden and Prothrombin G20210A in Healthy Southern Italians, 10.1177/1076029607310218
  68. Leroyer Christophe, Mottier Dominique, Mercier Bernard, Férec Claude, Escoffre Martine, Factor V Leiden Prevalence in Venous Thromboembolism Patients, 10.1378/chest.111.6.1603
  69. Bedenčič Mateja, Božič Mojca, Peternel Polona, Stegnar Mojca, Major and Potential Prothrombotic Genotypes in Patients with Venous Thrombosis and in Healthy Subjects from Slovenia, 10.1159/000173722
  70. Ben Salem-Berrabah Olfa, Fekih-Mrissa Nejiba, N’Siri Brahim, Ben Hamida Abdelmajid, Benammar-Elgaaied Amel, Gritli Nasreddine, Mrissa Ridha, Thrombophilic polymorphisms – factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T – in Tunisian patients with cerebral venous thrombosis, 10.1016/j.jocn.2011.11.029
  71. Gurgey A., Haznedaroglu I.C., Egesel T., Buyukas?k Y., Ozcebe O.I., Say?nalp N., Dundar S.V., Bayraktar Y., Two common genetic thrombotic risk factors: Factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis, 10.1002/ajh.1087
  72. Kupeli Elif, Verdi Hasibe, Simsek Abdullah, Atac Fatma Belgin, Eyuboglu Fusun Oner, Genetic Mutations in Turkish Population With Pulmonary Embolism and Deep Venous Thrombosis, 10.1177/1076029610385224
  73. Tug Esra, Aydin Hatip, Kaplan Ebru, Dogruer Dilek, Frequency of Genetic Mutations Associated with Thromboembolism in the Western Black Sea Region, 10.2169/internalmedicine.50.4144
  74. Almawi Wassim Y., Keleshian Sose H., Borgi Lobna, Fawaz Naglaa A., Abboud Nisreen, Mtiraoui Nabil, Mahjoub Touhami, Varied Prevalence of Factor V G1691A (Leiden) and Prothrombin G20210A Single Nucleotide Polymorphisms Among Arabs, 10.1007/s11239-005-3550-4
  75. Dowling N. F., Austin H., Dilley A., Whitsett C., Evatt B. L., Hooper W. C., The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study1 : Epidemiology of venous thromboembolism, 10.1046/j.1538-7836.2003.00031.x
  76. de Moerloose P., Reber G., Perrier A., Perneger T., Bounameaux H., Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism, 10.1046/j.1365-2141.2000.02039.x
  77. Domagala T. B., Adamek L., Nizankowska E., Sanak M., Szczeklik A., Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease : , 10.1097/00001721-200207000-00007
  78. Koeleman BP, Semin Hematol, 34, 256 (1997)
  79. Koster T, Blood, 85, 2756 (1995)
  80. Eid SS, Clin Lab Sci J Am Soc Med Technol, 15, 196 (2001)
  81. Ben-Tal O, Thromb Haemost, 61, 50 (1989)
  82. Franco Rendrik F., Reitsma Pieter H., Genetic risk factors of venous thrombosis, 10.1007/s004390100593
  83. Margaglione M., Grandone E., Population genetics of venous thromboembolism : A narrative review, 10.1160/th10-08-0510
  84. Angchaisuksiri Pantep, Atichartakarn Vichai, Aryurachai Katcharin, Archararit Napaporn, Rachakom Buppa, Atamasirikul Kanlayanee, Tiraganjana Arjit, Risk factors of venous thromboembolism in Thai patients, 10.1007/bf02983995
  85. Chen TY, Ann Hematol, 82, 114 (2003)
  86. Chafa O., Fischer A. M., Sternberg C., Meriane F., Millien C., Benabadji M., The relative frequency of inherited inhibitor deficiency among 93 young patients with thrombophilia in Algeria : , 10.1097/00001721-199308000-00017
  87. Van der Meer FJM, Thromb Haemost Stuttg, 78, 631 (1997)
  88. Remacha A. F., Estivill C., Sarda M. P., Mateo J., Souto J. C., Canals C., Nomdedeu J., Fontcuberta J., The V617F mutation of JAK2 is very uncommon in patients with thrombosis, 10.3324/haematol.10358
  89. UGO V., LE GAL G., LECUCQ L., MOTTIER D., OGER E., , Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism : Letters to the Editor, 10.1111/j.1538-7836.2007.02811.x
  90. Kralovics Robert, Passamonti Francesco, Buser Andreas S., Teo Soon-Siong, Tiedt Ralph, Passweg Jakob R., Tichelli Andre, Cazzola Mario, Skoda Radek C., A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders, 10.1056/nejmoa051113
  91. Wolanskyj Alexandra P., Lasho Terra L., Schwager Susan M., McClure Rebecca F., Wadleigh Martha, Lee Stephanie J., Gary Gilliland D., Tefferi Ayalew, JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance, 10.1111/j.1365-2141.2005.05764.x
  92. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi A M, Clinical implications of the JAK2 V617F mutation in essential thrombocythemia, 10.1038/sj.leu.2403902
  93. Cheung Betty, Radia Deepti, Pantelidis Panagiotis, Yadegarfar Ghasem, Harrison Claire, The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia, 10.1111/j.1365-2141.2005.05858.x
  94. Tefferi Ayalew, Lasho Terra L., Schwager Susan M., Strand Jacob S., Elliott Michelle, Mesa Ruben, Li Chin-Yang, Wadleigh Martha, Lee Stephanie J., Gilliland D. Gary, The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera, 10.1002/cncr.21645
  95. Colaizzo D., Amitrano L., Iannaccone L., Vergura P., Cappucci F., Grandone E., Guardascione M. A., Margaglione M., Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings, 10.1136/jmg.2006.048371
  96. REGINA S., HERAULT O., D'ALTEROCHE L., BINET C., GRUEL Y., JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis, 10.1111/j.1538-7836.2007.02384.x
  97. Za Tommaso, Fiorini Alessia, Rossi Elena, Ciminello Angela, Chiusolo Patrizia, Leone Giuseppe, De Stefano Valerio, Prevalence of theJAK2V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms, 10.1111/j.1365-2141.2008.07537.x
  98. Rossi Davide, Cresta Stefania, Destro Tamara, Vendramin Chiara, Bocchetta Simone, De Paoli Lorenzo, Cerri Michaela, Lunghi Monia, Gaidano Gianluca, JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia, 10.1111/j.1365-2141.2007.06715.x
  99. Pardanani Animesh, Lasho Terra L., Hussein Kebede, Schwager Susan M., Finke Cristy M., Pruthi Rajiv K., Tefferi Ayalew, JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients, 10.4065/83.4.457
  100. Bellucci S, Thromb Haemost, 99, 1119 (2008)
  101. De Stefano V, Thromb Haemost, 99, 1121 (2008)
  102. Xavier Sandra Guerra, Gadelha Telma, Schaffel Rony, Britto Luciana, Pimenta Glicínia, Ribeiro Daniel Dias, Sabino Adriano de Paula, Pires Virgínia, Renault Ilana Zalcberg, Spector Nelson, Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis : , 10.1097/mbc.0b013e328304e0a9
  103. PASSAMONTI S. M., BIGUZZI E., CAZZOLA M., FRANCHI F., GIANNIELLO F., BUCCIARELLI P., PIETRA D., MANNUCCI P. M., MARTINELLI I., The JAK2 V617F mutation in patients with cerebral venous thrombosis : JAK2 V617F mutation and cerebral venous thrombosis, 10.1111/j.1538-7836.2012.04719.x
  104. Patel Raj K., Lea Nicholas C., Heneghan Michael A., Westwood Nigel B., Milojkovic Dragana, Thanigaikumar Murugaiyan, Yallop Deborah, Arya Roopen, Pagliuca Antonio, Gäken Joop, Wendon Julia, Heaton Nigel D., Mufti Ghulam J., Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome, 10.1053/j.gastro.2006.04.008
  105. Primignani Massimo, Barosi Giovanni, Bergamaschi Gaetano, Gianelli Umberto, Fabris Federica, Reati Raffaella, Dell'Era Alessandra, Bucciarelli Paolo, Mannucci Pier Mannuccio, Role of theJAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis, 10.1002/hep.21435
  106. DE STEFANO V., FIORINI A., ROSSI E., ZA T., FARINA G., CHIUSOLO P., SICA S., LEONE G., Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders, 10.1111/j.1538-7836.2007.02424.x
  107. McMahon Christine, Abu-Elmagd Kareem, Bontempo Franklin A., Kant Jeffrey A., Swerdlow Steven H., JAK2V617F Mutation in Patients With Catastrophic Intra-abdominal Thromboses, 10.1309/ja1wd8jnvlgynqye
  108. Bayraktar Yusuf, Harmanci Ozgur, Büyükasik Yahya, Shorbagi Ali Ibrahim, Sungur Aysegul Hasegeli, Boylu Cemaliye Akyerli, Gürgey Aytemiz, Balkanci Ferhun, JAK2V617F Mutation in Patients with Portal Vein Thrombosis, 10.1007/s10620-008-0225-y
  109. GOULDING C., UTTENTHAL B., FORONI L., DUKE V., TRAORE A., KOTTARIDIS P., HOFFBRAND A. V., PATCH D., MCNAMARA C., TheJAK2V617Ftyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis, 10.1111/j.1751-553x.2007.00973.x
  110. Kiladjian J.-J., Cervantes F., Leebeek F. W. G., Marzac C., Cassinat B., Chevret S., Cazals-Hatem D., Plessier A., Garcia-Pagan J.-C., Murad S. D., Raffa S., Janssen H. L. A., Gardin C., Cereja S., Tonetti C., Giraudier S., Condat B., Casadevall N., Fenaux P., Valla D. C., The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases, 10.1182/blood-2007-11-125328
  111. Xavier Sandra Guerra, Gadelha Telma, Pimenta Glicínia, Eugenio Angela Maria, Ribeiro Daniel Dias, Gomes Fernanda Mendes, Bonamino Martin, Zalcberg Ilana Renault, Spector Nelson, JAK2V617F Mutation in Patients with Splanchnic Vein Thrombosis, 10.1007/s10620-009-0933-y
  112. XAVIER S. G., GADELHA T., REZENDE S. M., ZALCBERG I. R., SPECTOR N., JAK2V617F mutation in patients with thrombosis: to screen or not to screen? : SCREENING OF JAK2V617F MUTATION IN THROMBOSIS, 10.1111/j.1751-553x.2010.01275.x
  113. Xu X., Zhang Q., Luo J., Xing S., Li Q., Krantz S. B., Fu X., Zhao Z. J., JAK2V617F: prevalence in a large Chinese hospital population, 10.1182/blood-2006-03-009472
  114. De Tanima, Prabhakar Puttachandra, Nagaraja Dindagur, Christopher Rita, Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders, 10.1016/j.jns.2012.09.012
  115. Colaizzo Donatella, Amitrano Lucio, Guardascione Maria Anna, Tiscia Giovanni Luca, D'Andrea Giovanna, Longo Vittoria A.C., Grandone Elvira, Margaglione Maurizio, Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: A role for the JAK2 V617F mutation re-evaluation, 10.1016/j.thromres.2013.07.014
  116. Dentali F., Squizzato A., Brivio L., Appio L., Campiotti L., Crowther M., Grandi A. M., Ageno W., JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis, 10.1182/blood-2008-12-196014
  117. Arellano-Rodrigo E, Haematologica, 91, 169 (2006)
  118. Falanga Anna, Marchetti Marina, Vignoli Alfonso, Balducci Donatella, Russo Laura, Guerini Vittoria, Barbui Tiziano, V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules, 10.1016/j.exphem.2007.01.053
  119. Falanga A, Blood, 96, 4261 (2000)
  120. Chait Yasmine, Condat Bertrand, Cazals-Hatem Dominique, Rufat Pierre, Atmani Sai, Chaoui Driss, Guilmin Françoise, Kiladjian Jean Jacques, Plessier Aurélie, Denninger Marie Hélène, Casadevall Nicole, Valla Dominique, Brière Jean B., Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis, 10.1111/j.1365-2141.2005.05490.x
  121. Brière Jean, Budd-Chiari Syndrome and Portal Vein Thrombosis Associated with Myeloproliferative Disorders: Diagnosis and Management, 10.1055/s-2006-939432
  122. Haslam Karl, Langabeer Stephen E., Incidence ofCALRmutations in patients with splanchnic vein thrombosis, 10.1111/bjh.13121
  123. Turon Fanny, Cervantes Francisco, Colomer Dolors, Baiges Anna, Hernández-Gea Virginia, Garcia-Pagán Juan Carlos, Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis, 10.1016/j.jhep.2014.08.032